11 years of cyanopyrrolidines as DPP-IV inhibitors

Current Topics in Medicinal Chemistry

Volumn 7, Issue 6, 2007, Pages 579-595

  Peters, Jens Uwe ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Cyanopyrrolidine inhibitors; Cysteine protease inhibitors; NVP DPP728; Proline derivatives; STRUCTURE ACTIVITY RELATIONSHIPS

Indexed keywords

1 [4 METHYL 1 (2 PYRIMIDINYL) 4 PIPERIDYLAMINOACETYL] 2 PYRROLIDINECARBONITRILE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ADAMANTANE DERIVATIVE; AMINO ACID DERIVATIVE; CYANOPYRROLIDINE DERIVATIVE; DENAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DIPEPTIDYL PEPTIDASE IX INHIBITOR; DIPEPTIDYL PEPTIDASE VIII INHIBITOR; DP 893; FE 999011; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GSK 23A; HYDRAZINE DERIVATIVE; KR 62436; METFORMIN; MP 513; PEPTIDE HYDROLASE INHIBITOR; PEPTIDYLNITRILE; PLACEBO; PSN 9301; ROSIGLITAZONE; SAXAGLIPTIN; SERINE PROTEINASE INHIBITOR; SULFONYLUREA; SYR 322; UNCLASSIFIED DRUG; VILDAGLIPTIN;

CHEMICAL MODIFICATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STABILITY; DRUG SYNTHESIS; DRUG TARGETING; DYSLIPIDEMIA; EDEMA; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HYPOGLYCEMIA; IC 50; MOLECULAR INTERACTION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REACTION ANALYSIS; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION; TOXICITY TESTING; WEIGHT GAIN;

ANTIGENS, CD26; DIABETES MELLITUS, TYPE 2; HUMANS; PYRROLIDINES; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33947685466     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802607780091000     Document Type: Review

References (171)

1. Vats, R. K.; Kumar, V.; Kothari, A.; Mital, A. Emerging targets for diabetes. Curr. Science 2005, 88(2), 241-249.
2. Rotella, D. P. Novel "second-generation" approaches for the control of type 2 diabetes. J. Med. Chem. 2004, 47(17), 4111-4112.
3. Skyler, J. S. Diabetes mellitus: pathogenesis and treatment strategies. J. Med. Chem. 2004, 47, 4113-4117.
4. Chu-Moyer, M.Y. Patent focus on antidiabetic agents. Expert. Opin. Ther. Patents 2000, 10(6), 787-801.
5. Henke, B. R. Peroxisome proliferator-activated receptor α/γ dual agonists for the treatment of type 2 diabetes. J. Med. Chem. 2004, 47(17), 4118-4127.
6. Van Huijsduijnen, R. H.; Sauer, W. H. B.; Bombrun, A.; Swinnen, D. Prospects for inhibitors of protein tyrosin phosphatase 1B as antidiabetic drugs. J. Med. Chem. 2004, 47(17), 4142-4146.
7. Weber, A. E. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J. Med. Chem. 2004, 47(17), 4135-4141.
8. Augustyns, K.; Van der Veken, P.; Senten, K.; Haemers, A. The therapeutic potential of inhibitors of dipeptidyl peptidase IV (DPP IV) and related proline-specific dipeptidyl aminopeptidases. Curr. Med. Chem. 2005, 12, 971-998.
9. Hunziker, D.; Hennig, M.; Peters, J.-U. Inhibitors of dipeptidyl peptidase IV - recent advances and structural views. Curr. Top. Med. Chem. 2005, 5(16), 1623-1637.
10. Evans, D. M. Dipeptidyl peptidase IV inhibitors. IDrugs 2002, 5(6), 577-585.
11. McIntosh, C. H. S.; Demuth, H.-U.; Kim, S.-J.; Pospisilik, J. A.; Pederson, R. A. Applications of dipeptidyl peptidase IV inhibitors in diabetes mellitus. Int. J. Biochem. Cell Biol. 2006, 38(5-6), 860-872.
12. Augustyns, K.; Van der Veken, P.; Haemers, A. Inhibitors of proline-specific dipeptidyl peptidases: DPP-IV inhibitors as a novel approach for the treatment of type 2 diabetes. Expert Opin. Ther. Pat. 2005, 15(10), 1387-1407.
13. Wiedeman, P. E.; Trevillyan, J. M. Dipeptidyl peptidase IV inhibitors for type 2 diabetes and metabolic syndrome. Drug Discov. Today 2005, 2(2), 143-149.
14. Nielsen, L. L. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discov. Today 2005, 10(10), 703-710.
15. Demuth, H.-U.; McIntosh, C. H. S.; Pederson, R. A. Type 2 diabetes - therapy with dipeptidyl peptidase IV inhibitors. Biochim. Biophys. Acta 2005, 1751, 33-44.
16. Augustyns, K.; Van der Veken, P.; Senten, K.; Haemers, A. Dipeptidyl peptidase IV inhibitors as new therapeutic agents for the treatment of type 2 diabetes. Expert Opin. Ther. Pat. 2003, 13(4), 499-510.
17. Deacon, C. F.; Holst, J. J. Dipeptidyl peptidase IV inhibitors: A promising new therapeutic approach for the management of type 2 diabetes. Int. J. Biochem. Cell Biol. 2006, 38, 831-844.
18. Holst, J. J.; Deacon, C. F. Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus. Curr. Opin. Pharmacol. 2004, 4(6), 589-596.
19. Drucker, J. D. Enhancing Incretin action for the treatment of type 2 diabetes. Diabetes Care 2003, 26(10), 2929-2940.
20. Holst, J. J. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab. Res. Rev. 2002, 18(6), 430-441.
21. Knudsen, L. B. Glucagon-like peptide-1: The basis of a new class of treatment for type 2 diabetes. J. Med. Chem. 2004, 47(17), 4128-4134.
22. Edwards, C. M. B. GLP-1: target for a new class of antidiabetic agents? J. R. Soc. Med. 2004, 97(6), 270-274.
23. Vahl, T. P.; D'Alessio, D. A. Gut peptides in the treatment of diabetes mellitus. Expert Opin. Invest. Drugs 2004, 13(3), 177-188.
24. Nauck, M. A. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes. Horm. Met. Res. 2004, 36(11/12), 852-858.
25. Gallwitz, B. Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus. Treat. Endocrinol. 2005, 4(6), 361-370.
26. Drucker, J. D. Enhancing Incretin action for the treatment of type 2 diabetes. Diabetes Care 2003, 26(10), 2929-2940.
27. Huang, A.; Raskin, P. Glucagon-like peptide: The time is near. Basic Clin. Pharmacol. Toxicol. 2004, 95(6), 249-251.
28. Holst, J. J.; Orskov, C. The incretin approach for diabetes treatment. Modulation of islet hormone release by GLP-1 agonism. Diabetes 2004, 53(Suppl. 3), 197-204.
29. Deacon, C. F. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 2004, 53(9), 2181-2189.
30. Meier, J. J.; Gallwitz, B.; Nauck, M. A. Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus. BioDrugs 2003, 17(2), 93-102.
31. Villhauer, E. B.; Brinkman, J. A.; Naderi, G. B.; Dunning, B. E.; Mangold, B. L.; Mone, M. D.; Russell, M. E.; Weldon, S. C.; Hughes, T. E. 1-[2-[(5-Cyanopyridin-2-yl)amino]ethylamino] acetyl-2-(S)-pyrrolidinecarbonitrile: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties. J. Med. Chem. 2002, 45(12), 2362-2365.
32. Villhauer, E. B. Preparation of N-aminoacetyl-2-cyanopyrrolidines as dipeptidylpeptidase IV inhibitors. PCT Int. Appl. WO9819998 A2, 1998.
33. Hughes, T. E.; Mone, M. D.; Russell, M. E.; Weldon, S. C.; Villhauer, E. B. NVP-DPP728 (1- [2-[(5-Cyanopyridin-2-yl) amino]ethyl]amino]acetyl]-2-cyano-(S)-pyrrolidine), a Slow-Binding Inhibitor of Dipeptidyl Peptidase IV. Biochemistry 1999, 38(36), 11597-11603.
34. Kanstrup, A. B.; Christiansen, L. B.; Lundbeck, J. M.; Sams, C. K.; Kristiansen, M. Preparation of piperazinylpurinediones as inhibitors of dipeptidylpeptidase IV. PCT. Int. Appl. WO2002002560, 2002.
35. Schoen, E.; Born, I.; Demuth, H. U.; Faust, J.; Neubert, K.; Steinmetzer, T.; Barth, A.; Ansorge, S. Dipeptidyl peptidase IV in the immune system. Effects of specific enzyme inhibitors on activity of dipeptidyl peptidase IV and proliferation of human lymphocytes. Biol. Chem. Hoppe-Seyler 1991, 372(5), 305-311.
36. Pospisilik, J. A.; Stafford, S. G.; Demuth, H-U.; Brownsey, R.; Parkhouse, W.; Finegood, D. T.; McIntosh, C. H. S.; Pederson, R. A. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and b-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 2002, 51(4), 943-950.
37. Sorbera, L. A.; Revel, L.; Castaner, J. P32/98: Antidiabetic dipeptidyl-peptidase IV inhibitor. Drugs Fut. 2001, 26(9), 859-864.
38. Feng, J.; Gwaltney, S. L.; Stafford, J. A.; Zang, Z. Preparation of pyrimidine-2,4-dione compounds as dipeptidyl peptidase IV inhibitors. Jpn. Kokai Tokkyo Koho, JP 2005263780, 2005.
39. Kim, D.; Wang, L.; Beconi, M.; Eiermann, G. J.; Fisher, M. H.; He, H.; Hickey, G. J.; Kowalchick, J. E.; Leiting, B.; Lyons, K.; Marsilio, F.; McCann, M. E.; Patel, R. A.; Petrov, A.; Scapin, G.; Patel, S. B.; Roy, R. S.; Wu, J. K.; Wyvratt, M. J.; Zhang, B. B.; Zhu, L.; Thornberry, N. A.; Weber, A. E. (2R)-4-Oxo-4-[3- (Trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: A Potent, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes. J. Med. Chem. 2005, 48(1), 141-151.
40. McIntyre, J. A.; Castaner, J. Vildagliptin: Agent for type 2 diabetes, dipeptidyl-peptidase IV inhibitor. Drugs Fut. 2004, 29(9), 887-891.
41. Barlocco, D. LAF-237 Novartis. Curr. Opin. Invest. Drugs 2004, 5(10), 1094-1100.
42. Villhauer, E. B.; Brinkman, J. A.; Naderi, G. B.; Burkey, B. F.; Dunning, B. E.; Prasad, K.; Mangold, B. L.; Russell, M. E.; Hughes, T. E. 1- (3-Hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: A Potent, Selective, and Orally Bioavailable Dipeptidyl Peptidase IV Inhibitor with Antihyperglycemic Properties. J. Med. Chem. 2003, 46(13), 2774-2799.
43. Westerik, J. O.; Wolfenden, R. Aspartic b-semialdehyde, a potent inhibitor of Escherichia coli L-asparaginase. J. Biol. Chem.1974, 249(19), 6351-6353.
44. Lowe, G.; Yuthavong, Y. pH-dependence and structure-activity relations in the papain-catalyzed hydrolysis of anilides. Biochem. J. 1971, 124(1), 117-122.
45. Thompson, S. A.; Andrews, P. R.; Hanzlik, R. P. Carboxyl-modified amino acids and peptides as protease inhibitors. J. Med. Chem. 1986, 29(1), 104-111.
46. Leung, D.; Abbenante, G.; Fairlie, D. P. Protease inhibitors: Current status and future prospects. J. Med Chem. 2000, 43(3), 305-341.
47. Tanaka, Y.; Niwa, S.; Nishioka, H.; Yamanaka, T.; Torizuka, M.; Yoshinaga, K.; Kobayashi, N.; Ikeda, Y.; Arai, H. New Potent Prolyl Endopeptidase Inhibitors: Synthesis and Structure-Activity Relationships of Indan and Tetralin Derivatives and Their Analogs. J. Med. Chem. 1994, 37(13), 2071-2078.
48. Flentke, G. R.; Munoz, E.; Huber, B. T.; Plant, A. G.; Kettner, C. A.; Bachovchin, W. W. Inhibition of dipeptidyl aminopeptidase IV (DP-IV) by Xaa-boroPro dipeptides and use of these inhibitors to examine the role of DP-IV in T-cell function. Proc. Natl. Acad. Sci. U. S. A. 1991, 88(4), 1556-1559.
49. Coutts, S. J.; Kelly, T. A.; Snow, R. J.; Kennedy, C. A.; Barton, R. W.; Adams, J.; Krolikowski, D. A.; Freeman, D. M.; Campbell, S. J.; Ksiazek, J. F.; Bachovchin, W. W. Structure-Activity Relationships of Boronic Acid Inhibitors of Dipeptidyl Peptidase IV. 1. Variation of the P2 Position of Xaa-boroPro Dipeptides. J. Med. Chem. 1996, 39(10), 2087-2094.
50. Boduszek, B.; Oleksyszyn, J.; Kam, C.-M.; Selzler, J.; Smith, R. E.; Powers, J. C. Dipeptide Phosphonates as Inhibitors of Dipeptidyl Peptidase IV. J. Med. Chem. 1994, 37(23), 3969-3976.
51. Lambeir, A.-M.; Borloo, M.; De Meester, I.; Belyaev, A.; Augustyns, K.; Hendriks, D.; Scharpe, S.; Haemers, A. Dipeptide-derived diphenyl phosphonate esters: mechanism-based inhibitors of dipeptidyl peptidase IV. Biochim. Biophys. Acta, Gen. Subj. 1996, 1290(1), 76-82.
52. Belyaev, A.; Zhang, X.; Augustyns, K.; Lambeir, A.-M.; De Meester, I.; Vedernikova, I.; Scharpe, S.; Haemers, A. Structure-Activity Relationship of Diaryl Phosphonate Esters as Potent Irreversible Dipeptidyl Peptidase IV Inhibitors. J. Med. Chem. 1999, 42(6), 1041-1052.
53. Senten, K.; Danieels, L.; Van der Veken, P.; De Meester, I.; Lambeir, A.-M.; Scharpe, S.; Haemers, A.; Augustyns, K. Rapid Parallel Synthesis of Dipeptide Diphenyl Phosphonate Esters as Inhibitors of Dipeptidyl Peptidases. J. Comb. Chem. 2003, 5(3), 336-344.
54. Demuth, H. U.; Neumann, U.; Barth, A. Reactions between dipeptidyl peptidase IV and diacyl hydroxylamines: mechanistic investigations. J. Enzyme Inhib. 1989, 2(4), 239-248.
55. Li, J.; Wilk, E.; Wilk, S. Aminoacylpyrrolidine-2-nitriles: potent and stable inhibitors of dipeptidyl-peptidase IV (CD 26). Arch. Biochem. Biophys. 1995, 323(1), 148-154.
56. Ashworth, D. M.; Atrash, B.; Baker, G. R.; Baxter, A. J.; Jenkins, P. D.; Jones, D. M.; Szelke, M. 2-Cyanopyrrolidides as potent, stable inhibitors of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett. 1996, 6(10), 1163-1166.
57. Ashworth, D. M.; Atrash, B.; Baker, G. R.; Baxter, A. J.; Jenkins, P. D.; Jones, D. M.; Szelke, M. 4-Cyanothiazolidides as very potent, stable inhibitors of dipeptidyl peptidase IV. Bioorg. Med. Chem. Lett. 1996, 6(22), 2745-2748.
58. Jenkins, P. D.; Jones, D. M.; Szelke, M. Preparation of peptide analog DP-IV serine protease inhibitors. PCT Int. Appl. WO9515309, 1995.
59. Fleischer, B. CD26: a surface protease involved in T-cell activation. Immunol. Today 1994, 15(4), 180-184.
60. Ahren, B.; Simonsson, E.; Larsson, H.; Landin-Olsson, M.; Torgeirsson, H.; Jansson, P.-A.; Sandqvist, M.; Bavenholm, P.; Efendic, S.; Eriksson, J. W.; Dickinson, S.; Holmes, D. Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. Diabetes Care 2002, 25(5), 869-875.
61. Villhauer, E. B. Preparation of N-glycyl-2-cyanopyrrolidines as DPP IV inhibitors. PCT Int. Appl. WO2000034241 A1, 2000.
62. Robl, J. A.; Sulsky, R. B.; Augeri, D. J.; Magnin, D. R.; Hamann, L. G.; Betebenner, D. A. Preparation of fused cyclopropyl-pyrrolidine-based inhibitors of dipeptidyl peptidase IV. PCT Int. Appl. WO2001068603 A2, 2001.
63. Augeri, D. J.; Robl, J. A.; Betebenner, D. A.; Magnin, D. R.; Khanna, A.; Robertson, J. G.; Wang, A.; Simpkins, L. M.; Taunk, P.; Huang, Q.; Han, S.-P.; Abboa-Offei, B.; Cap, M.; Xin, L.; Tao, L.; Tozzo, E.; Welzel, G. E.; Egan, D. M.; Marcinkeviciene, J.; Chang, S. Y.; Biller, S. A.; Kirby, M. S.; Parker, R. A.; Hamann, L. G. Discovery and Preclinical Profile of Saxagliptin (BMS-477118): A Highly Potent, Long-Acting, Orally Active Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type 2 Diabetes. J. Med. Chem. 2005, 48(15), 5025-5037.
64. Pueschel, G.; Mentlein, R.; Heymann, E. Isolation and characterization of dipeptidyl peptidase IV from human placenta. Europ. J. Biochem. 1982, 126(2), 359-365.
65. Heins, J.; Welker, P.; Schoenlein, C.; Born, I.; Hartrodt, B.; Neubert, K.; Tsuru, D.; Barth, A. Mechanism of proline-specific proteinases: (I). Substrate specificity of dipeptidyl peptidase IV from pig kidney and proline-specific endopeptidase from Flavobacterium meningosepticum. Biochim. Biophys. Acta 1988, 954(2), 161-169.
66. Rahfeld, J.; Schutkowski, M.; Faust, J.; Neubert, K.; Barth, A.; Heins, J. Extended investigation of the substrate specificity of dipeptidyl peptidase IV from pig kidney. Biolog. Chem. Hoppe-Seyler 1991, 372(5), 313-318.
67. Hopsu-Havu, V. K.; Glenner, G. G. New dipeptide naphthylamidase hydrolyzing glycylprolyl-b-naphthylamide. Histochemie 1966, 7(3), 197-201.
68. Engel, M.; Hoffmann, T.; Wagner, L.; Wermann, M.; Heiser, U.; Kiefersauer, R.; Huber, R.; Bode, W.; Demuth, H.-U.; Brandstetter, H. The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(9), 5063-5068.
69. Lautar, S. L.; Rojas, C.; Slusher, B. S.; Wozniak, K. M.; Wu, Y.; Thomas, A. G.; Waldon, D.; Li, W.; Ferraris, D.; Belyakov, S. DPP IV inhibitor blocks mescaline-induced scratching and amphetamine-induced hyperactivity in mice. Brain Res. 2005, 1048(1-2), 177-184.
70. Sankaranarayanan, A. Preparation of thiazolidine-4-carbonitriles and analogs and their use as dipeptidyl-peptidase inhibitors. U.S. Pat. Appl. Publ. US2004106802 A1, 2004.
71. Sankaranarayanan, A. Preparation of thiazolidine-4-carbonitriles and analogs and their use as dipeptidyl-peptidase inhibitors. PCT Int. Appl. WO2003084940 A1, 2003.
72. Villhauer, E. B. N-Substituted glycyt-2-cyanopyrrolidines as a new family of DPP4 inhibitors and their potential in type 2 diabetes. Presentation at the Cambridge Healthtech Institute's 11th Annual MolecularMedicine Tri-conference, San Francisco, March 23-26, 2004.
73. Kanstrup, A. B.; Lundbeck, J. M.; Christiansen, L. B.; Kristiansen, M.; Christensen, L.; Christensen, I. T.; Bowler, A. N. Preparation of 2-cyanopyrroles and their analogues as DPP-IV inhibitors. PCT Int. Appl. WO 2004089362 A1, 2004.
74. Nilsson, C.; Westman, A.; Blennow, K.; Ekman, R. Processing of neuropeptide Y and somatostatin in human cerebrospinal fluid as monitored by radioimmunoassay and mass spectrometry. Peptides 1998, 19(7), 1137-1146.
75. Tomboly, C.; Peter, A.; Toth, G. In vitro quantitative study of the degradation of endomorphins. Peptides 2002, 23(9), 1573-1580.
76. Ahmad, S.; Wang, L.; Ward, P. E. Dipeptidyl(amino)peptidase IV and aminopeptidase M metabolize circulating substance P in vivo. J. Pharmacol. Exp. Ther. 1992, 260(3), 1257-1261.
77. Guieu, R.; Fenouillet, E.; Devaux, C.; Fajloun, Z.; Carrega, L.; Sabatier, J.-M.; Sauze, N.; Marguet, D. CD26 modulates nociception in mice via its dipeptidyl-peptidase IV activity. Behav.Brain Res. 2006, 166(2), 230-235.
78. Magnin, D. R.; Robl, J. A.; Sulsky, R. B.; Augeri, D. J.; Huang, Y.; Simpkins, L. M.; Taunk, P. C.; Betebenner, D. A.; Robertson, J. G.; Abboa-Offei, B. E.; Wang, A.; Cap, M.; Xin, L.; Tao, L.; Sitkoff, D. F.; Malley, M. F.; Gougoutas, J. Z.; Khanna, A.; Huang, Q.; Han, S.-P.; Parker, R. A.; Hamann, L. G. Synthesis of Novel Potent Dipeptidyl Peptidase IV Inhibitors with Enhanced Chemical Stability: Interplay between the N-Terminal Amino Acid Alkyl Side Chain and the Cyclopropyl Group of a-Aminoacyl-L-cis-4,5-methanoprolinenitrile-Based Inhibitors. J. Med. Chem. 2004, 47(10), 2587-2598.
79. Fukushima, H.; Hiratate, A.; Takahashi, M.; Saito, M.; Munetomo, E.; Kitano, K.; Saito, H.; Takaoka, Y.; Yamamoto, K. Synthesis and structure-activity relationships of potent 3- or 4-substituted-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. 2004, 12(23), 6053-6061.
80. Fukushima, H. Hiratate, A.; Takahashi, M.; Kameo, K. Preparation of 2-cyanopyrrolidine derivatives as dipeptidyl peptidase IV (DPPIV) inhibitors. PCT Int. Appl. WO2002038541 A1, 2002.
81. Pitt, G. R. W.; Evans, D. M. Preparation of amino acid 3-fluoropyrrolidinamides as antidiabetic agents. PCT Int. Appl. WO 2003000250 A1, 2003.
82. Haffner, C. D.; McDougald, D. L.; Randhawa, A. S.; Reister, S. M.; Lenhard, J. M. Preparation of fluoropyrrolidinecarbonitrile derivatives as dipeptidyl peptidase inhibitors. PCT Int. Appl. WO2003002531, 2003.
83. Haffner, C. D.; McDougald, D. L.; Lenhard, J. M. Preparation of fluoropyrrolidinecarbonitrile derivatives as dipeptidyl peptidase inhibitors. PCT Int. Appl. WO2003002553 A2, 2003.
84. Madar, D.; Pei, Z.; Pireh, D.; Djuric, S. W.; Wiedeman, P. E.; Yong, H.; Feenstra, M. J.; Kopecka, H.; Li, X.; Longenecker, K.; Sham, H. L.; Stewart, K. D.; Szczepankiewicz, B. G. Preparation of N-aminoacyl pyrrolidine-2-carbonitriles and related compounds as inhibitors of dipeptidyl peptidase-IV (DPP-IV) useful against type II diabetes and other disorders. PCT Int. Appl. WO2004026822 A2, 2004.
85. Madar, D. J.; Djuric, S. W.; Michmerhuizen, M. J.; Kopecka, H. A.; Li, X.; Longenecker, K. L.; Pei, Z.; Pireh, D.; Sham,, H. L.; Stewart K. D.; Szczepankiewicz, B. G.; Wiedeman, P. E.; Yong, H. Preparation of N-aminoacyl pyrrolidine-2-carbonitriles and related compounds as inhibitors of dipeptidyl peptidase-IV (DPP-IV) useful against type II diabetes and other disorders. U.S. Pat. Appl. Publ. US2004259843 A1, 2004.
86. Madar, D. J.; Djuric, S. W.; Michmerhuizen, M. J.; Kopecka, H. A.; Li, X.; Longenecker, K. L.; Pei, Z.; Pireh, D.; Sham, H. L.; Stewart, K. D.; Szczepankiewicz, B. G.; Wiedeman, P. E.; Yong, H. Preparation of cyanopyrrolidine derivatives and pharmaceutical compositions thereof as inhibitors of dipeptidyl peptidase-iv (dpp-iv). U.S. Pat. Appl. Publ. US2005215784 A1, 2005.
87. McClure, L. D.; Olson, T. V.; Wright, S. W. Preparation of dicyanopyrrolidines as dipeptidyl peptidase IV inhibitors. PCT Int. Appl. WO2005095339 A1, 2005.
88. Lankas, G. R.; Leiting, B.; Roy, R. S.; Eiermann, G. J.; Beconi, M. G.; Biftu, T.; Chan, C.-C.; Edmondson, S.; Feeney, W. P.; He, H.; Ippolito, D. E.; Kim, D.; Lyons, K. A.; Ok, H. O.; Patel, R. A.; Petrov, A. N.; Pryor, K. A.; Qian, X.; Reigle, L.; Woods, A.; Wu, J. K.; Zaller, D.; Zhang, X.; Zhu, L.; Weber, A. E.; Thornberry, N. A. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes. Potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes 2005, 54(10), 2988-2994.
89. Sulsky, R. B.; Robl, J. A. Preparation of 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV. PCT Int. Appl. WO2002083128 A1, 2002.
90. Ahn, J. H.; Kim, H.-M.; Jung, S. H.; Kang, S. K.; Kim, K. R.; Rhee, S. D.; Yang, S.-D.; Cheon, H. G.; Kim, S. S. Synthesis and DP-IV inhibition of cyano-pyrazoline derivatives as potent antidiabetic agents. Bioorg. Med. Chem. Lett. 2004, 14(17), 4461-4465.
91. Kim, K.-R.; Rhee, S.-D.; Kim, H. Y.; Jung, W. H.; Yang, S.-D.; Kim, S. S.; Ahn, J. H.; Cheon, H. G. KR-62436, 6-{2-[2-(5-cyano-4,5-dihydropyrazol-1-yl)-2-oxoethylamino]ethylamino} nicotinonitrile, is a novel dipeptidyl peptidase-IV (DPP-IV) inhibitor with anti-hyperglycemic activity. Europ. J. Pharmacol. 2005, 518(1) 63-70.
92. Magnin, D. R.; Taunk, P. C.; Robertson, J. G.; Wang, A.; Marcinkeviciene, J.; Kirby, M. S.; Hamann, L. G. Secoprolinenitrile inhibitors of dipeptidyl peptidase IV define minimal pharmacophore requirements at P1. Bioorg. Med. Chem. Lett. 2006, 16(6), 1731-1734.
93. Magnin, D. R.; Hamann, L. G. Preparation of glycinenitrile-based inhibitors of dipeptidyl peptidase IV. PCT Int. Appl. WO2004037181 A2.
94. Tsutsumi, K.; Shinkai, H.; Kitao, Y.; Yamashita, M.; Kobayashi, S.; Matsui, K.; Oda, T.; Taniguchi, T.; Asahina, K. Preparation of amino acid derivatives as dipeptidyl peptidase IV inhibitors. PCT Int. Appl. WO2005025554 A2, 2005.
95. Bondebjerg, J.; Fuglsang, H.; Naerum, L. Preparation of peptidyl nitriles as protease inhibitors. PCT Int. Appl. WO2004110988 A1, 2004.
96. Sudre, B.; Broqua, P.; White, R. B.; Ashworth, D.; Evans, D. M.; Haigh, R.; Junien, J.-L.; Aubert, M. L. Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes 2002, 51(5), 1461-1469.
97. Qiao, L.; Baumann, C. A.; Crysler, C. S.; Ninan, N. S.; Abad, M. C.; Spurlino, J. C.; DesJarlais, R. L.; Kervinen, J.; Neeper, M. P.; Bayoumy, S. S.; Williams, R.; Deckman, I. C.; Dasgupta, M.; Reed, R. L.; Huebert, N. D.; Tomczuk, B. E.; Moriarty, K. J. Discovery, SAR, and X-ray structure of novel biaryl-based dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett. 2006, 16(1), 123-128.
98. Kitashima, H.; Yoshida, T.; Sonda, S.; Akaboshi, F.; Hayashi, Y. Preparation of N-(a-aminoacyl)-2-cyanopyrrolidine derivatives as inhibitors of dipeptidyl peptidase IV (DPP-IV) for drugs. Jpn. Kokai Tokkyo Koho JP2002265439 A2, 2002.
99. Lu, I-L.; Lee, S.-J.; Tsu, H.; Wu, S.-Y.; Kao, K.-H.; Chien, C.-H.; Chang, Y.-Y.; Chen, Y.-S.; Cheng, J.-H.; Chang, C.-N.; Chen, T.-W.; Chang, S.-P.; Chen, X.; Jiaang, W.-T. Glutamic acid analogues as potent dipeptidyl peptidase IV and 8 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15(13), 3271-3275.
100. De Nanteuil, G.; Portevin, B.; Benoist, A.; Levens, N.; Nosjean, O.; Husson-Robert, B.; Boulanger, M. Preparation of a-amino acid derivatives and their use as inhibitors of dipeptidyl-peptidase IV (DPP IV). Eur. Pat. Appl. EP1258476 A1, 2003.
101. Evans, D. M.; Pitt, G. R. W. Preparation of peptidomimetics as inhibitors of dipeptidyl peptidase IV. PCT Int. Appl. WO2001081304 A1, 2001.
102. Joshi, H. V.; Gopalan, B.; Shah, D. M.; Thomas, A. Preparation of cyclopropylglycine dipeptides as inhibitors of dipeptidyl peptidase. PCT Int. Appl. WO2005058849 A1, 2005.
103. Haffner, C. D.; McDougald, D. L.; Randhawa, A. S.; Reister, S. M.; Lenhard, J. M. Preparation of fluoropyrrolidinecarbonitrile derivatives as dipeptidyl peptidase inhibitors. PCT Int. Appl. WO2003002531 A2, 2003.
104. Heins, J.; Welker, P.; Schoenlein, C.; Born, I.; Hartrodt, B.; Neubert, K.; Tsuru, D.; Barth, A. Mechanism of proline-specific proteinases: (1). Substrate specificity of dipeptidyl peptidase IV from pig kidney and proline-specific endopeptidase from Flavobacterium meningosepticum. Biochim. Biophys. Acta 1988, 954(2), 161-169.
105. Villhauer, E. B. Preparation of 1-glycyl-2-cyanopyrrolidines as dipeptidyl peptidase-IV inhibitors. US patent appl. US6011155, 2000.
106. Villhauer, E. B. Preparation of aminoacetylthiazolidines as inhibitors of dipeptidyl peptidase-IV. US patent appl. US6107317, 2000.
107. Villhauer, E. B. Preparation of 3-[(alkylamino)acetyl]-4-cyanothiazolidines as dipeptidyl peptidase IV inhibitors. US patent appl. US6110949, 2000.
108. Villhauer, E. B. Preparation of N-glycyl-2-cyanopyrrolidines as DPP IV inhibitors. PCT Int. Appl. WO2001096295 A2, 2001.
109. Hayakawa, M.; Negoro, K.; Miyamoto, S.; Suzuki, T.; Maruyama, T.; Nakano, R. Preparation of 2-cyano-4-fluoropyrrolidine derivatives as dipeptidylpeptidase (DPP) IV inhibitors. PCT Int. Appl. WO2004009544 A1, 2004.
110. Gopalan, B.; Joshi, H. V.; Shah, D. M.; Ghorpade, S. R. Preparation of pyrrolidinylamine-substituted carbazoles as dipeptidyl peptidase IV inhibitors. PCT Int. Appl. WO2005033099 A2, 2005.
111. De Nanteuil, G.; Benoist, A.; Combettes, M.; Harley, E. Pyrrolidine and thiazolidine derivatives, their preparation and their use as dipeptidyl peptidase IV (DPP IV) inhibitors in the treatment of hyperglycemia and diabetes type II. Eur. Pat. Appl. EP1598350 A1, 2005.
112. Aranyi, P.; Balazs, L.; Bata, I.; Batori, S.; Boronkay, E.; Bovy, P.; Kanai, K.; Kapui, Z.; Susan, E.; Szabo, T.; Nagy, L. T.; Urban-Szabo, K.; Varga, M. Preparation of aminoacetylpyrrolidine-carbonitriles as inhibitors of DPP-IV. PCT Int. Appl. WO2003074500 A2, 2003.
113. Thomas, A.; Gopalan, B.; Lingam, V. S. Prasada R.; Shah, D. M. Preparation of glycinamide derivatives as dipeptidyl peptidase IV inhibitors. PCT Int. Appl. WO2005075426 A1, 2005.
114. Thomas, A.; Balasubramanian, G.; Lingam, P. R. V. S.; Shah, D. M. Preparation of pyrrolidine derivatives as inhibitors of dipeptidyl peptidase IV. PCT Int. Appl. WO2006011035 A1, 2006.
115. Feng, J.; Gwaltney, S. L.; Stafford, J. A.; Wallace, M. B.; Xiao, X.-Y.; Zhang, Z. Preparation of homochiral pyrrolidine derivatives as dipeptidyl peptidase (DPP IV) inhibitors. PCT Int. Appl. WO2004103993 A1, 2004.
116. Chen, W.-T.; Kelly, T. Seprase complexes in cellular invasiveness. Cancer Metastasis Rev. 2003, 22(2/3), 259-269.
117. Kelly, T. Fibroblast activation protein-a and dipeptidyl peptidase IV (CD26): Cell-surface proteases that activate cell signaling and are potential targets for cancer therapy. Drug Resistance Updates 2005, 8(1-2), 51-58.
118. Pierau, S.; Oefner, C.; Dale, G. E. Preparation of novel peptidomimetics for inhibition of dipeptidyl peptidase (DPP-IV) and neprilysin (NEP) and/ or angiotensin converting enzyme (ACE). U.S. Pat. Appl. Publ. US 2006046978 A1, 2006.
119. Plamboeck, A.; Holst, J. J.; Carr, R.D.; Deacon, C. F. Neutral endopeptidase 24.11 and dipeptidyl peptidase IV are both involved in regulating the metabolic stability of glucagon-like peptide-1 in vivo. Adv. Exp. Med. Biol. 2003, 524(Dipeptidyl Aminopeptidases in Health and Disease), 303-312.
120. Hupe-Sodmann, K.; Goke, R.; Goke, B.; Thole, H. H.; Zimmermann, B.; Voigt, K.; McGregor, G. P. Endoproteolysis of glucagon-like peptide (GLP)-1(7-36) amide by ectopeptidases in RINm5F cells. Peptides 1997, 18(5), 625-632.
121. Hupe-Sodmann, K.; McGregor, G. P.; Bridenbaugh, R.; Goeke, R.; Goeke, B.; Thole, H.; Zimmermann, B.; Voigt, K. Characterization of the processing by human neutral endopeptidase 24.11 of GLP-1(7-36)amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul. Pept. 1995, 58(3), 149-156.
122. Arbin, V.; Claperon, N.; Fournie-Zaluski, M.-C.; Roques, B. P.; Peyroux, J. Acute effect of the dual angiotensin-converting enzyme and neutral endopeptidase 24-11 inhibitor mixanpril on insulin sensitivity in obese Zucker rat. Br. J. Pharmacol. 2001, 133(4), 495-502.
123. Arbin, V.; Claperon, N.; Fournie-Zaluski, M.-C.; Roques, B. P.; Peyroux, J. Effects of Dual Angiotensin-Converting Enzyme and Neutral Endopeptidase 24-11 Chronic Inhibition by Mixanpril on Insulin Sensitivity in Lean and Obese Zucker Rats. J. Cardiovasc. Pharmacol. 2003, 41(2), 254-264.
124. Yang, C.; Hsu, W. H. Glucose-dependency of bradykinin-induced insulin secretion from the perused rat pancreas. Regul. Pept. 1997, 71(1), 23-28.
125. Thoma, R.; Loffler, B.; Stihle, M.; Huber, W.; Ruf, A.; Hennig, M. Structural Basis of Proline-Specific Exopeptidase Activity as Observed in Human Dipeptidyl Peptidase-IV. Structure 2003, 11(8), 947-959.
126. Damon, R. Preparation of tetrahydroisoquinoline-3-carboxamide derivatives as inhibitors of DPP-IV. U.S. Patent Appl. US6172081 B1, 2001.
127. Zhao, G.; Taunk, P. C.; Magnin, D. R.; Simpkins, L. M.; Robl, J. A.; Wang, A.; Robertson, J. G.; Marcinkeviciene, J.; Sitkoff, D. F.; Parker, R. A.; Kirby, M.S.; Hamann, L. G. Diprolyl nitriles as potent dipeptidyl peptidase IV inhibitors. Bioorg. Med. Chem. Lett. 2005, 15(18), 3992-3995.
128. Kitajima, H.; Sakashita, H.; Akahoshi, F.; Hayashi, Y. Preparation of proline derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors and use thereof as drugs. PCT Int. Appl. WO2002014271 A1, 2002.
129. Sakashita, H.; Kitajima, H.; Nakamura, M.; Akahoshi, F.; Hayashi, Y. 1-((S)-g-Substituted prolyl)-(S)-2-cyanopyrrolidine as a novel series of highly potent DPP-IV inhibitors. Bioorg. Med. Chem. Lett. 2005, 15(10), 2441-2445.
130. Hulin, B.; Piotrowski, D. W. Preparation of 4-(nitrogen-heterocyclic-amino)pyrrolidine-2-carboxamides as dipeptidyl peptidase-IV inhibitors for treating diabetic complications and other disorders. U.S. Pat. Appl. US2005256310 A1, 2005.
131. Nakai, H.; Kondo, T.; Yamamoto, S. Preparation of proline derivatives as DPP4 inhibitors. PCT Int. Appl. WO2005073186 A1, 2005.
132. Ohkawa, T.; Imamura, K.; Kurosaki, T.; Kobayashi, M.; Shimizu, S. Preparation of pyrrolidine, thiazolidine and oxazolidine compounds which inhibit dipeptidyl peptidase-IV (DPP). PCT Int. Appl. WO2004111041 A1, 2004.
133. Pei, Z.; Li, X.; Longenecker, K. L.; Sham, H. L.; Wiedeman, P. E. Preparation of pyrrolidine-2-carbonitrile derivatives and their use as inhibitors of dipeptidyl peptidase-IV (DPP-IV). PCT Int. Appl. WO2005023762 A1, 2005.
134. Shima, I.; Kuroda, A.; Ohkawa, T.; Kurosaki, T.; Sawada, Y.; Wada, A. Preparation of azabicycle-containing 2-cyanopyrrolidinecarboxamides as dipeptidyl peptidase-IV inhibitors useful for treating non-insulin-dependent diabetes mellitus. U.S. Pat. Appl. US2005137224 A1, 2005.
135. Hayakawa, M.; Negoro, K.; Suzuki, T.; Maruyama, T.; Nakano, R. Preparation of 1-(a-aminoacyl)azetidine-2-carbonitrile derivatives or salts thereof as dipeptidyl peptidase IV inhibitors. PCT Int. Appl. WO2004007446 A1, 2004.
136. Evans, D.M. Preparation of 1-(2′-aminoacyl)-2-cyanopyrrolidine derivatives as novel antidiabetic agents. PCT Int. Appl. WO2001040180 A2, 2001.
137. Pitt, Gary Robert William; Evans, David Michael. Preparation of amino acid 3-fluoropyrrolidinamides as antidiabetic agents. PCT Int. Appl. WO2003000250 A1, 2003.
138. Evans, D. M.; Tartar, A. Novel dipeptidyl peptidase IV (DP-IV) inhibitors as anti-diabetic agents. PCT Int. Appl. WO2003035067 A1, 2003.
139. Fukushima, H.; Hiratate, A.; Takahashi, M.; Kameo, K. Preparation of N-(aminoacyl)cyanofluoropyrrolidine derivatives as dipeptidyl peptidase IV inhibitors. PCT Int. Appl. WO2003095425 A1, 2003.
140. Fukushima, H.; Hiradate, A.; Takahashi, M.; Kameo, K. Pharmaceuticals containing cyanopyrrolidine derivatives as dipeptidyl peptidase IV inhibitors. Jpn. Kokai Tokkyo Koho JP2005139107 A2, 2005.
141. Lin, J.; Toscano, P. J.; Welch, J. T. Inhibition of dipeptidyl peptidase IV by fluoroolefin-containing N-peptidyl-O-hydroxylamine peptidomimetics. Proc. Nat. Acad. Sci. U.S.A. 1998, 95(24), 14020-14024.
142. Zhao, K.; Lim, D. S.; Funaki, T.; Welch, J. T. Inhibition of dipeptidyl peptidase IV (DPP IV) by 2-(2-amino-1-fluoropropylidene)-cyclopentanecarbonitrile, a fluoroolefin containing peptidomimetic. Bioorg. Med. Chem. 2003, 11(2), 207-215.
143. Van der Veken, P.; Senten, K.; Kertesz, I.; De Meester, I.; Lambeir, A.-M.; Maes, M.-B.; Scharpe, S.; Haemers, A.; Augustyns, K. Fluoro-Olefins as Peptidomimetic Inhibitors of Dipeptidyl Peptidases. J. Med. Chem. 2005, 48(6), 1768-1780.
144. Schoenafinger, K.; Wagner, H.; Jaehne, G.; Gaul, H.; Buning, C.; Tschank, G.; Werner, U. Preparation of 3-cyanopyrrolizidines for the treatment of type 2 diabetes. PCT Int. Appl. WO 2005012308 A1, 2005.
145. Wagner, H.; Schoenafinger, K.; Jaehne, G.; Gaul, H.; Buning, C.; Tschank, G.; Werner, U. Preparation of 6-amino-3-cyano-5-oxohexahydropyrrolo[2,1-b]thiazoles as dipeptidyl peptidase IV (DPP-IV) inhibitors. PCT Int. Appl. WO2005012312 A1, 2005.
146. Yasuda, K.; Morimoto, H.; Kawanami, S.; Hikota, M.; Matsumoto, T.; Arakawa, K. Preparation of nitrogenous five-membered ring compounds such as (S)-N-[N-cyclohexyl or N-(4-piperidinyl)glycyl]pyrrolidine-2-carbonitrile derivatives as dipeptidyl peptidase IV inhibitors. PCT Int. Appl. WO2002030890 A1, 2002.
147. Takasaki, K.; Iwase, M.; Nakajima, T.; Ueno, K.; Nomoto, Y.; Nakanishi, S.; Higo, K. K579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent. Europ. J. Pharmacol. 2004, 486(3), 335-342.
148. Takasaki, K.; Takada, H.; Nakajima, T.; Ueno, K.; Ushiki, J.; Higo, K. Involvement of the active metabolites in the inhibitory activity of K579 on rat plasma dipeptidyl peptidase IV. Europ. J. Pharmacol. 2004, 505(1-3), 237-241.
149. von Geldern, T. DPP-IV inhibitors, oral presentation at the Frontiers in Medicinal Chemistry, Frankfurt (Germany), March 12-15, 2006.
150. Shima, I.; Kurosaki, T.; Wada, A. Preparation of 1-(2-aminoacetyl)-2-cyanopyrrolidines as dipeptidyl peptidase-IV inhibitors for treatment of NIDDM. PCT Int. Appl. WO2004099185 A1, 2004.
151. Hayakawa, M.; Nakano, R.; Furutani, M. Preparation of piperidine compounds containing pyrrolidine moiety as DPP-IV inhibitors. WO2005116012 A1, 2005.
152. Fukuda, Y.; Asahina, Y.; Katayama, S.; Shibue, T.; Murakami, K.; Ide, T. Preparation of pyrrolidine compounds having bicyclic amide moiety as DPP-IV inhibitors. PCT Int. Appl. WO2005077900 A1, 2005.
153. Fukuda, Y.; Asahina, Y.; Ohata, K.; Yokota, K.; Murakami, K.; Matsui, T. Preparation of pyrrolidine compounds having bicyclic moiety as DPP-IV inhibitors. PCT Int. Appl. WO2005075421 A1, 2005.
154. Fukuda, Y.; Asahina, Y.; Yokota, K.; Murakami, K.; Ide, T. Preparation of pyrrolidine compounds having bicyclic amide moiety as DPP-IV inhibitors. PCT Int. Appl. WO2005082847 A1, 2005.
155. Parker, J. C.; Wright, S. W.; Olson, T. V.; Doran, S. D.; Soglia, C. B.; Vanvolkenburg, M. A.; Andrews, K. M.; McPherson, K.; Treadway, J. L. 2,5-Dicyanopyrrolidine based DPP-IV inhibitors. Presentation at the 65th Scientific Sessions of the American Diabetes Association, San Diego, CA, USA, June 10-14, 2005.
156. Boehringer, M.; Hunziker, D.; Kuehne, H.; Loeffler, B. M.; Sarabu, R.; Wessel, H. P. Preparation of N-aminoacetyl-substituted pyrrolidines as dipeptidyl peptidase IV inhibitors. PCT Int. Appl. WO2003037327 A1, 2003.
157. Toyama, Y.; Yokota, M.; Yamamoto, F.; Kosakai, K. Preparation of 4-substituted-2-cyanopyrrolidine derivatives, pharmaceutical compositions and dipeptidyl peptidase IV inhibitors containing them, and their uses. Jpn. Kokai Tokkyo Koho JP2004244412 A2, 2004.
158. Fukushima, H.; Takahashi, M.; Mikami, A. Preparation of cyanofluoropyrrolidine derivatives as dipeptidylpeptidase IV inhibitors. PCT Int. Appl. WO2004101514 A1, 2004.
159. Kakigami, T.; Oka, M.; Katoh, N.; Yoshida, M.; Shirai, M.; Murase, T.; Sakairi, M.; Yamamoto, T.; Takeuchi, M.; Hayashi, Y.; Takeda, M.; Makino, M. Preparation of arylcarboxamides as dipeptidyl peptidase IV inhibitors. PCT Int. Appl. WO2004067509 A1, 2004.
160. Tsu, H.; Chen, X.; Chen, C.-T.; Lee, S.-J.; Chang, C.-N.; Kao, K.-H.; Coumar, M. S.; Yeh, Y.-T.; Chien, C.-H.; Wang, H.-S.; Lin, K.-T.; Chang, Y.-Y.; Wu, S.-H.; Chen, Y.-S.; Lu, I-L.; Wu, S.-Y.; Tsai, T.-Y.; Chen, W.-C.; Hsieh, H.-P.; Chao, Y.-S.; Jiaang, W.-T. 2-[3-[2-[(2S)-2-Cyano-1-pyrrolidinyl]-2-oxoethylamino]-3-methyl-1- oxobutyl]- 1,2,3,4-tetrahydroisoquinoline: A Potent, Selective, and Orally Bioavailable Dipeptide-Derived Inhibitor of Dipeptidyl Peptidase IV. J. Med. Chem. 2006, 49(1), 373-380.
161. Jiaang, W.-T.; Chen, X.; Wu, S.-Y.; Hsieh, H.-P.; Chao, Y.-S. Preparation of pyrrolidine derivatives as inhibitors of dipeptidyl peptidase IV (DPP-IV). PCT Int. Appl. WO2005087235 A1, 2005.
162. Royalty, S. M.; Burns, J. F.; Scicinski, J. J.; Foglesong, R. J.; Jagdmann, G. E., Jr.; Griffin, K. R.; Dyakonov, T.; Middlemiss, D. 1-Aminoacetyl-2-cyanopyrrolidine derivatives as dipeptidyl peptidase IV inhibitors and their preparation, pharmaceutical compositions, and use for treatment of diabetes. PCT Int. Appl. WO2006012441 A1, 2006.
163. Royalty, S. M.; Burns, J. F.; Scicinski, J. J.; Jagdmann, G. E., Jr.; Foglesong, R. J.; Griffin, K. R.; Dyakonov, T.; Middlemiss, D. 1-Aminoacetyl-2-cyanopyrrolidine derivatives as dipeptidyl peptidase IV inhibitors and their preparation, pharmaceutical compositions, and use for treatment of diabetes. PCT Int. Appl. WO2006012395 A2, 2006
164. Aranyi, P.; Bata, I.; Batori, S.; Boronkay, E.; Bovy, P.; Kapui, Z.; Susan, E.; Szabo, T.; Urban-szabo, K.; Varga, M. Preparation of pyrrolidinecarbonitrile compounds and analogs for DPP-IV enzyme inhibition. PCT Int. Appl. WO2005021536 A2, 2005.
165. Haffner, C. D.; McDougald, D. L.; Reister, S. M.; Thompson, B. D.; Conlee, C.; Fang, J.; Bass, J.; Lenhard, J. M.; Croom, D.; Secosky-Chang, M. B.; Tomaszek, T.; McConn, D.; Wells-Knecht, K.; Johnson, P. R. 2-Cyano-4-fluoro-1-thiovalylpyrrolidine analogues as potent inhibitors of DPP-IV. Bioorg. Med. Chem. Lett. 2005, 15(23), 5257-5261.
166. Barlocco, D. LAF-237 Novartis. Curr. Opin. Invest. Drugs 2004, 5(10), 1094-1100.
167. Pratley, R.; Galbreath, E. Twelve-week monotherapy with the DPP-4 inhibitor LAF237 improves glycemic control in patients with type 2 diabetes (T2DM). American Diabetes Association, 64th Annual Scientific Sessions 2004, Orlando Florida, Abstract 355-OR.
168. McIntyre, J. A.; Castaner, J. Vildagliptin: Agent for type 2 diabetes dipeptidyl-peptidase IV inhibitor. Drugs Fut. 2004, 29(9), 887-891.
169. Ahren, B.; Gomis, R.; Standl, E.; Mills, D.; Schweizer, A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 2004, 27(12), 2874-2880.
170. Ristic, S.; Byiers, S.; Foley, J.; Holmes, D. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: Vildagliptin (LAF237) dose response. Diabetes, Obesity and Metabolism 2005, 7(6), 692-698.
171. Data presented by Bristol-Myers Squibb at their November 2004 investor meeting.